News

Warren is an internationally recognized expert in pediatric neuro-oncology. Her work focuses on rational, pharmacokinetic-based drug development for children with brain tumors, and she is a leading innovator in developing new means of drug delivery.

Vrooman will share the abstract at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Researchers call for expanding children’s access to experimental cancer therapies

Stand Up To Cancer (SU2C) announced on May 2 that a team led by Kimberly Stegmaier, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Sarah Tasian, MD, Children's Hospital of Philadelphia, was awarded a two-year grant totaling $250,000. Their SU2C Sharp Award is titled: Precision combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR) signaling in pediatric and young adult CRLF2-rearranged ALL.

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy to treat two of the most common inherited blood diseases, sickle cell disease and beta thalassemia, applying CRISPR-Cas9 gene editing to patients' own blood stem cells.

The Go4theGoal Foundation (G4TG) recently awarded Brian Crompton, MD, of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, a $50,000 research grant.

The International Society for Stem Cell Research (ISSCR) announced that Scott Armstrong, MD, PhD, is the recipient of its 2019 Tobias Award Lecture.

Pre-treatment with an antibody-drug combination avoids side effects in mice; could substitute for current toxic regimens using chemotherapy or radiation

Multi-center study led by Dana-Farber/Boston Children's contributes to FDA approval of a new treatment for acute lymphoblastic leukemia

The research will focus on adapting gene therapy for use in low-resource areas with high rates of the disease.